CIK 0000914475 · Large accelerated filer
NEUROCRINE BIOSCIENCES INC
Sign in to watch- Ticker
- NBIX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 330525145
- Phone
- (858) 617-7600
- Business address
- 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,162,347
- in 4 filings, $3.2M under 10b5-1 plans
Net −$3,162,347. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-25 | MORROW GEORGE J Director | Sale 10b5-1 | −15,000 | $143.37 | $2.2M | 7,068 |
| 2025-11-25 | MORROW GEORGE J Director | Option exercise · Non-Qualified Stock Option 10b5-1 | −15,000 | 0 | ||
| 2025-11-05 | RASTETTER WILLIAM H Director | Option exercise 10b5-1 | +18,000 | $47.89 | $862K | 58,360 |
| 2025-11-05 | RASTETTER WILLIAM H Director | Sale 10b5-1 | −18,000 | $151.82 | $2.7M | 40,360 |
| 2025-11-05 | RASTETTER WILLIAM H Director | Option exercise · Non-Qualified Stock Option 10b5-1 | −18,000 | 0 | ||
| 2025-11-04 | Gano Kyle Chief Executive Officer | Sale | −300 | $141.97 | $43K | 140,407 |
| 2025-11-01 | Gano Kyle Chief Executive Officer | Option exercise | +613 | 140,720 | ||
| 2025-11-01 | Gano Kyle Chief Executive Officer | Option exercise · Restricted Stock Unit | −613 | 1,842 | ||
| 2025-09-03 | Onyia Jude Chief Scientific Officer | Gift | −1,470 | 13,703 | ||
| 2025-09-02 | SHERWIN STEPHEN A Director | Gift | −1,000 | 12,542 | ||
| 2025-08-07 | GORMAN KEVIN CHARLES Director | Option exercise 10b5-1 | +106,322 | $35.99 | $3.8M | 620,918 |
| 2025-08-07 | GORMAN KEVIN CHARLES Director | Sale 10b5-1 | −106,322 | $126.41 | $13.4M | 514,596 |
| 2025-08-07 | GORMAN KEVIN CHARLES Director | Option exercise · Non-Qualified Stock Option 10b5-1 | −106,322 | 0 | ||
| 2025-08-05 | Onyia Jude Chief Scientific Officer | Gift | −3,116 | 15,173 | ||
| 2025-07-10 | Delaet Ingrid Chief Regulatory Officer | Option exercise 10b5-1 | +457 | $79.02 | $36K | 5,187 |
| 2025-07-10 | Delaet Ingrid Chief Regulatory Officer | Sale 10b5-1 | −457 | $135.00 | $62K | 4,730 |
| 2025-07-10 | Delaet Ingrid Chief Regulatory Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −457 | 2,261 | ||
| 2025-07-09 | Onyia Jude Chief Scientific Officer | Option exercise 10b5-1 | +59,819 | $84.74 | $5.1M | 78,108 |
| 2025-07-09 | Onyia Jude Chief Scientific Officer | Sale 10b5-1 | −59,819 | $130.46 | $7.8M | 18,289 |
| 2025-07-09 | Onyia Jude Chief Scientific Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −59,819 | 35,268 |
Page 17 of 49 · 963 trades